Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice

Background: Recent clinical trials indicate that sodium–glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in myocardial infarction (MI) patients, but the underlying mechanisms remain unknown. As arrhythmia often occurs during myocardial infarction, it is the main cause of de...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Genlong Xue, Xiaolei Yang, Ge Zhan, Xin Wang, Jinghan Gao, Yong Zhao, Xinying Wang, Jiatian Li, Zhenwei Pan, Yunlong Xia
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-10-01
coleção:	Frontiers in Pharmacology
Assuntos:	sodium–glucose cotransporter 2 empagliflozin myocardial infarction membrane potential intracellular Ca2+
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.988408/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!